<DOC>
	<DOCNO>NCT02273635</DOCNO>
	<brief_summary>The purpose study compare efficacy safety andrographolide 140 mg administer twice day orally versus placebo modify treatment disease patient progressive form Multiple Sclerosis ( MS ) . The principal outcome determine efficacy , andrographolide retard progression brain atrophy patient progressive form MS .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Andrographolides Versus Placebo Patients With Progressive Forms MS</brief_title>
	<detailed_description>1 . Evaluate clinical efficacy andrographolide 140 mg administer orally twice day versus placebo : - Delay disability capacity progression Expanded Disability Status Scale ( EDSS ) Multiple Sclerosis Functional Composite ( MSFC ) 24 month compare baseline . - Delay cognitive impairment mean Paced Auditory Serial Addition Test ( PASAT ) , Symbol Digit Modalities Test ( SDMT ) depression ( Beck ) 24 month compare baseline . - Quality life Multiple Sclerosis Impact Scale ( MSIS 29 ) fatigue ( Krupp ) parameter report patient 24 month compare baseline . - Tolerability andrographolide measure Treatment Satisfaction Questionnaire Medication ( TSQM ) 24 month . - Delay decrease brain volume measure Magnetic Resonance ( MR ) 24 month compare baseline . - Number volume new lesion large size T2 MR 24 month compare baseline . - Number new hipointense lesion T1 ( gadolinium captive ) MR 24 month compare baseline . - Delay retineal thin measure Optical Coherence Tomography ( OCT ) visual field 24 month compare baseline . - Safety andrographolide 24 month record adverse effect symptom dairy program interview . 2 . Explore pharmacokinetic andrographolide 140 mg administer orally twice day : - bio availability concentration andrographolide patient treatment . - half-life , maximum concentration , clearance andrographolide equilibrium state . 3 . Determine immunomodulatory effect andrographolide 140 mg administer twice day orally lymphocyte population patient : - Determination Th1 , Th2 , Th17 Treg lymphocyte sub-populations . - Determination cytokine IFNgama , TNFalpha , IL2 , IL17alpha TGFbeta . Population : adult patient , men woman progressive form MS . The number patient select 68 , randomly assign 34 patient group .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Andrographolide</mesh_term>
	<criteria>Signed Informed Consent previous initiation study evaluation . Men woman &gt; 18 year age Minimental &gt; 24 . Patients diagnosis secondary progressive MS without relapse primary progressive MS accord criterion McDonald 2010 . Relapsingremitting MS Current Immunomodulatory immunosuppressive therapy Uncontrolled systemic disease control treat immunotherapy ( i.e Rheumatoid Arthritis , Lupus Erythematosus ) . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>